View
218
Download
4
Category
Preview:
Citation preview
2 / CONFIDENTIAL and PROPRIETARY
our focus
DISCOVERY CLINICAL DEVELOPMENT COMMERCIALIZATION
INNOVATION in Aesthetics and Dermatology
3 / CONFIDENTIAL and PROPRIETARY
the sienna opportunity
EXCEPTIONAL TEAM with a track record of success across leading global brands
UNIQUELY FOCUSED on developing aesthetic and dermatology products that will change
the practice of medicine
CLEAR STRATEGY for building pipeline of early to late stage novel assets
BUILD MULTI-ASSET PIPELINE first asset secured
4 / CONFIDENTIAL and PROPRIETARY
sienna’s vision to build a leading aesthetic company
Founding vision
! Apply high scientific rigor to aesthetics and dermatology
! Develop and commercialize innovative products that add value to patients and physician’s practice
Near-term execution
! Develop and commercialize Silver Plasmonic Therapy (SPT) for light hair removal and acne
! Maximize the value of SPT platform through expansion in new indications
! Aggressively expand product portfolio / pipeline
Long-term strategy
! Leverage world-class team’s experience in aesthetics and dermatology
! Build a leading portfolio
! Establish commercial leadership with Dermatologists, Plastic Surgeons, and Core Aesthetic Physicians
5 / CONFIDENTIAL and PROPRIETARY
clear strategy for building our pipeline
Innovative breakthroughs
SCIENCE
Aesthetics and Dermatology MARKET
Minimum $250 - $500M peak sales per product COMMERCIAL OPPORTUNITIES
Self pay and reimbursed REIMBURSEMENT
Develop a Comprehensive Pipeline of Early
to Late Stage Novel Assets
6 / CONFIDENTIAL and PROPRIETARY
our vision: bring innovative products to market which change the practice of medicine
AESTHETIC AND DERMATOLOGY TARGETS
HAIR REMOVAL
and GROWTH CONTOURING ACNE/
ROSACEA ATOPIC
DERMATITIS PSORIASIS SKIN
REJUVENATION
AESTHETIC DERMATOLOGY
7 / CONFIDENTIAL and PROPRIETARY
leading team in aesthetic and medical dermatology Frederick C. Beddingfield III MD, PhD President and CEO
• Former Chief Medical Officer
• Former VP and Head of Dermatology and Aesthetics R&D
• Associate Clinical Professor of Dermatology
Paul F. Lizzul MD, PhD Chief Medical Officer
Jere Fellmann PhD Head of Development Operations
• Former Vice President of Research
• Former Director, Lead Discovery and Molecular Biology
• Former Sr. Medical Director
• Former Assoc. Director Clinical Research, Dermatology
• Former Chief Financial Officer
• Former VP of Finance and Administration
• Former VP Clinical Operations
• Former Director of Clinical Affairs and PRIALT® WW Program Development Lead
Serge Lichtsteiner PhD Head of Research
Diane Stroehmann MS, RAC Chief of Staff and Head of Regulatory Affairs & Quality
Todd Harris PhD President of Sienna Labs and Head of Corporate Development
Ted Schwarz Head of Global Strategic Marketing
• Former VP of Regulatory Affairs, PV, and Research Compliance
• Former Head of Regulatory Affairs
• Founder & CEO
• Former Manager
• Former NIH Fellow and Doctoral Student
• Former President
• Former President
• Former Director of Global Marketing & Business Development
John W. Smither Chief Financial Officer
Susan Lundeen Vice President, Human Resources
• Former VP Human Resources
• Former VP Human Resource and Administration
Majed Kheir MBA Vice President, Operations
• Former Executive Dir. Supply Chain and Planning
• Former Director Operations Strategic Planning
8 / CONFIDENTIAL and PROPRIETARY
strong board
Frederick C. Beddingfield III MD, PhD Co-Founder, President and CEO Sienna Biopharmaceuticals
Todd Harris PhD Founder and President Sienna Labs, Head of Corporate Development, Sienna Biopharmaceuticals
Keith Leonard Executive Chairman
Former CEO, Kythera
Robert Nelsen Co-Founder, Managing Director, ARCH Venture Partners
Kristina Burow Managing Director, ARCH Venture Partners
Bob More MBA Chairman, One Revolution
9 / CONFIDENTIAL and PROPRIETARY
this team has developed top brands
DERMATOLOGY PRODUCTS AESTHETIC PRODUCTS
FROM DISCOVERY TO COMMERCIALIZATION AT GLOBAL COMPANIES
10 / CONFIDENTIAL and PROPRIETARY
team’s demonstrated success commercializing new scientific breakthroughs
65+ PRODUCTS
WORKED ON
100 INTERNATIONAL
REGULATORY FILINGS AND APPROVALS FOR VARIOUS INDICATIONS
6 FDA ADVISORY COMMITTEES
17 FDA
APPROVALS
11 / CONFIDENTIAL and PROPRIETARY
track record of driving meaningful value
Unanimous FDA Advisory Committee
(17-0)
KYBELLA® (U.S.) and BELKYRA®
(Canada) Regulatory Approvals
KYTH-105 (setipiprant) In-licensing
and IND Acceptance
12 / CONFIDENTIAL and PROPRIETARY
silver plasmonic therapy
• Breakthrough technology: silver plasmonic therapy • Based on the science of plasmonic resonance • Secured through Sienna Labs
OVERVIEW
• Light hair removal • Acne • Potential for skin rejuvenation
UNMET NEEDS
• Works with current existing base of energy devices • Expands populations who are candidates for treatment
MARKET
• Clinical proof-of-concept: – Prolonged efficacy – Favorable safety profile
• Aggressive and expanding IP portfolio: – 9 issued patents – 20+ patents pending
• Aesthetic product which benefits doctor and patients and a clear regulatory pathway for approval
– Class II device – 510(k) clearance
STATUS
13 / CONFIDENTIAL and PROPRIETARY
ULTRA EFFICIENT, NEAR INFRARED LIGHT ABSORBING SILVER BASED PARTICLES
• Contained in a topical pre-treatment solution
• Activation by a pulse of laser light causes a burst of energy
• Energy thermally changes the sebaceous glands and pores
• Particles do not penetrate through the epithelial barriers
Heat
Oscillations of Electrons
Near-IR Light
E-field
what are plasmonic particles?
14 / CONFIDENTIAL and PROPRIETARY
an innovative mechanism of action
OVERVIEW
CLINICAL RESULT Selective Restructuring of Pilosebaceous Unit
Hair: Permanent reduction in terminal hair counts including light-pigmented hair Acne: Prolonged reduction in acne lesions
Near-IR Light
DARK HAIR REMOVAL by Selective Photothermolysis
LIGHT HAIR REMOVAL with Silver Plasmonic Therapy
Near-IR Light
Thermal Injury Zone
Plasmonic Particles
Delivered to the Pilosebaceous
Unit and Activated with
Light
15 / CONFIDENTIAL and PROPRIETARY
SILVER PLASMONIC THERAPY
large, unmet needs
$250M - $500M PEAK YEAR OPPORTUNITY PER INDICATION
No Effective Solution
• $2B+ procedure market1
• 6M procedure opportunity4
Lack of Effective Procedural Solutions
ACNE
• $3B+ prescription market2
• 7M procedure opportunity4
LIGHT HAIR REMOVAL
1. Medical Insight Inc., 2. IMS Data, 3. ASAPS 2014, 4. company market research and analysis
16 / CONFIDENTIAL and PROPRIETARY
opportunities for expansion with SPT
Time
$
Existing laser hair removal consumers with light / mixed hair
Light hair consumers
being turned away AND
acne sufferers seeking
treatment from Derms
Potential for expansion
in hair removal:
• Darker skin • Increased
efficacy in all hair types
Potential for other future
indications:
• Rosacea • Sebaceous
gland hyperplasia
• Keratosis Pyloris
Recommended